<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383614</url>
  </required_header>
  <id_info>
    <org_study_id>DNDI-EMO-02</org_study_id>
    <secondary_id>2017-003020-75</secondary_id>
    <nct_id>NCT03383614</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside</brief_title>
  <official_title>A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of
      emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in
      healthy male caucasian subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an urgent need for a macrofilaricidal drug, killing or sterilizing permanently O.
      volvulus adult worms, which could be used in individual case management and, after
      appropriate testing, as an alternative drug to ivermectin in Mass Drug Administration (MDA)
      programs. Emodepside is a promising candidate to kill the adult and sexually mature O.
      volvulus as explained below. Emodepside was shown to be macrofilaricidal against a variety of
      filarial nematodes and is a registered drug for animal health, commercialized by Bayer AG
      under the name of Profender® (in combination with praziquantel) or Procox® (in combination
      with toltrazuril).

      A first-in-human (FIH) double-blind, placebo-controlled study of single ascending doses of
      emodepside in healthy Caucasian men has been conducted and the preliminary results are
      favourable, supporting continuation of the Phase I development program. In the present repeat
      dose study, PK as well as safety and tolerability of the liquid service formulation of
      emodepside, given over 10 days, will be tested.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Actual">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">October 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events</measure>
    <time_frame>up to 120 days</time_frame>
    <description>Death, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Adverse Event Severity</measure>
    <time_frame>Up to 120 days</time_frame>
    <description>Number of subjects with a TEAE, by highest level of severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Vital Signs Findings</measure>
    <time_frame>up to 120 days</time_frame>
    <description>Vital signs included heart rate, systolic and diastolic blood pressure and temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With 12-lead Electrocardiogram Findings</measure>
    <time_frame>up to 30 days</time_frame>
    <description>The following variables were recorded in 12-lead ECGs: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Clinical Laboratory Tests Findings</measure>
    <time_frame>up to 120 days</time_frame>
    <description>Clinical laboratory parameters included clinical chemistry, hematology, coagulation and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Ophthalmology Assessment Findings</measure>
    <time_frame>up to 10 days</time_frame>
    <description>Ophthalmological examinations at Screening Visit 2 and Day 10 were done at a specialist eye hospital by a Consultant Ophthalmologist, or their assistant. Examinations included: ocular symptoms and history, autorefraction, best correct visual acuity, colour vision, Amsler grid, ocular alignment and motility, confrontation visual field, slit-lamp, measurement of intraocular pressure and an optical coherence tomography test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Physical Examination Findings</measure>
    <time_frame>up to 120 days</time_frame>
    <description>Abnormal or clinically significant physical examination findings during the study or reported as an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Neurological Examination Findings</measure>
    <time_frame>up to 120 days</time_frame>
    <description>Abnormal or clinically significant neurological examination findings during the study or reported as an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Emodepside Plasma Pharmacokinetic Concentration−Time Data During the Repeated Dosing Period</measure>
    <time_frame>From Day 1, pre-dose to Day 9, 24 hours post-dose</time_frame>
    <description>Summary of geometric mean emodepside plasma pharmacokinetic concentration−time data (ng/mL) during the repeated dosing period (Days 0-9) in healthy men.
Subjects in the 10 mg emodepside BID dosing group had twice-daily doses on Days 0-8 and a single dose on the morning of Day 9. Therefore, the Day 9, 24 h post-dose value was not comparable to the previous value in that dosing group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUClast of Emodepside in Plasma</measure>
    <time_frame>AUClast in plasma after the last dose (Day 9)</time_frame>
    <description>Summary of AUClast of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration.
PK=pharmacokinetic. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUClast/D of Emodepside in Plasma</measure>
    <time_frame>AUClast /D in plasma after the last dose (Day 9)</time_frame>
    <description>Summary of AUClast/D of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast/D: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUClast,Norm of Emodepside in Plasma</measure>
    <time_frame>AUClast,norm in plasma after the last (Day 9) dose</time_frame>
    <description>Summary of AUClast,norm of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast,norm: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC12 of Emodepside in Plasma</measure>
    <time_frame>AUC12 in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of AUC12 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12: the area under the concentration-time curve from time zero (pre-dose) to 12h.
Note: AUC12 was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC12/D of Emodepside in Plasma</measure>
    <time_frame>AUC12/D in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of AUC12/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12/D: the area under the concentration-time curve from time zero (pre-dose) to 12h, corrected for dose.
Note: AUC12/D was collected only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC12,Norm of Emodepside in Plasma</measure>
    <time_frame>AUC12,norm in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of AUC12,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC12,norm: the area under the concentration−time curve from time zero (pre-dose) to 12 h corrected by dose and body weight.
Note: AUC12,norm was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC24 of Emodepside in Plasma</measure>
    <time_frame>AUC24 in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of AUC24 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24: the area under the concentration-time curve from time zero (pre-dose) to 24 h.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC24/D of Emodepside in Plasma</measure>
    <time_frame>AUC24/D in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of AUC24/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24/D: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC24,Norm of Emodepside in Plasma</measure>
    <time_frame>AUC24,norm in plasma at Day 0 and Day 9</time_frame>
    <description>Summary of AUC24,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC24,norm: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cmax of Emodepside in Plasma</measure>
    <time_frame>Cmax in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of Cmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cmax/D of Emodepside in Plasma</measure>
    <time_frame>Cmax/D in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of Cmax/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax/D: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cmax,Norm of Emodepside in Plasma</measure>
    <time_frame>Cmax,norm in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of Cmax,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax,norm: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Ctrough of Emodepside in Plasma</measure>
    <time_frame>Ctrough in plasma after the last (Day 9) dose</time_frame>
    <description>Summary of Ctrough (log-transformed) of emodepside after last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Ctrough: trough plasma concentration (measured concentration at the end of a dosing interval on Day 9 [taken directly before next administration]) obtained directly from the concentration-time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Tmax of Emodepside in Plasma</measure>
    <time_frame>tmax in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
    <description>Summary of tmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
tmax: the time at which Cmax was apparent, identified by inspection of the drug concentration vs. time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The t1/2 of Emodepside in Plasma</measure>
    <time_frame>t1/2 in plasma after the last (Day 9) dose</time_frame>
    <description>Summary of t1/2 of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2: terminal half-life. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The t1/2,(0-24) of Emodepside in Plasma</measure>
    <time_frame>t1/2,(0-24) in plasma after the last (Day 9) dose</time_frame>
    <description>Summary of t1/2,(0-24) of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2,(0-24): half-life calculated from the terminal slope of the log concentration-time (0-24h) curve.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The λz of Emodepside in Plasma</measure>
    <time_frame>λz in plasma after the last (Day 9) dose</time_frame>
    <description>Summary of λz of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
λz: terminal rate constant. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The CLss/F of Emodepside in Plasma</measure>
    <time_frame>CLss/F in plasma after the last (Day 9) dose</time_frame>
    <description>Summary of CLss/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
CLss/F: apparent total clearance from plasma on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Vz/F of Emodepside in Plasma</measure>
    <time_frame>Vz/F in plasma after the last (Day 9) dose</time_frame>
    <description>Summary of Vz/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Vz/F: apparent volume of distribution on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The MRTlast of Emodepside in Plasma</measure>
    <time_frame>MRTlast in plasma after the first (Day 0) dose</time_frame>
    <description>Summary of MRTlast of emodepside after the first (Day 0) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose.
MRTlast: mean residence time from time zero (pre-dose) to the time of last quantifiable concentration (measurable up to 24h after dosing on Day 0).
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rac(AUC12) of Emodepside in Plasma</measure>
    <time_frame>Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9)</time_frame>
    <description>Summary of emodepside plasma Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC12): accumulation ratio calculated from AUC12, where AUC12 is the area under the concentration−time curve from time zero (pre-dose) to 12h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).
Note: Rac(AUC12) was calculated only in Cohort 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rac(AUC24) of Emodepside in Plasma</measure>
    <time_frame>Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9)</time_frame>
    <description>Summary of emodepside plasma Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC24): accumulation ratio calculated from AUC24, where AUC24 is the area under the concentration-time curve from time zero (pre-dose) to 24h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rac(Cmax) of Emodepside in Plasma</measure>
    <time_frame>Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9)</time_frame>
    <description>Summary of emodepside plasma Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(Cmax): accumulation ratio calculated from Cmax, where Cmax is the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Concentration at Day -1</measure>
    <time_frame>Mean glucose at Day -1 after repeated once or twice daily dosing</time_frame>
    <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Concentration at Day 0</measure>
    <time_frame>Mean glucose after repeated once or twice daily dosing for up to 10 days</time_frame>
    <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Concentration at Day 9</measure>
    <time_frame>Mean glucose at Day 9 after repeated once or twice daily dosing</time_frame>
    <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Concentration at Day 30</measure>
    <time_frame>Mean glucose at Day 30 after repeated once or twice daily dosing</time_frame>
    <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insulin Concentration at Day -1</measure>
    <time_frame>Mean insulin concentration at Day-1 after repeated once or twice daily dosing</time_frame>
    <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insulin Concentration at Day 0</measure>
    <time_frame>Mean insulin concentration at Day 0 after repeated once or twice daily dosing</time_frame>
    <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insulin Concentration at Day 9</measure>
    <time_frame>Mean insulin concentration at Day 9 after repeated once or twice daily dosing</time_frame>
    <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insulin Concentration at Day 30</measure>
    <time_frame>Mean insulin concentration at Day 30 after repeated once or twice daily dosing</time_frame>
    <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Glucose Concentration at Day -2</measure>
    <time_frame>Mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Glucose Concentration at Day 1</measure>
    <time_frame>Mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Glucose Concentration at Day 8</measure>
    <time_frame>Mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Glucose Concentration at Day 120</measure>
    <time_frame>Mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Insulin Concentration at Day -2</measure>
    <time_frame>Mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Insulin Concentration at Day 1</measure>
    <time_frame>Mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Insulin Concentration at Day 8</measure>
    <time_frame>Mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Insulin Concentration at Day 120</measure>
    <time_frame>Mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution</time_frame>
    <description>Oral glucose tolerance test: mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug-related Adverse Events</measure>
    <time_frame>Drug-related AEs were reported throughout the study</time_frame>
    <description>Subjects presenting drug-related treatment-emergent adverse events listed by preferred term.
Note: subjects with ≥1 adverse event are counted only once per preferred term.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Filariasis</condition>
  <arm_group>
    <arm_group_label>cohort 1 (8 subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2 (8 subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3 (8 subjects)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LSF emodepside (BAY 44-4400) or matching placebo</intervention_name>
    <description>Emodepside administered as an LSF oral solution (1mg/mL)</description>
    <arm_group_label>cohort 1 (8 subjects)</arm_group_label>
    <arm_group_label>cohort 2 (8 subjects)</arm_group_label>
    <arm_group_label>cohort 3 (8 subjects)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, Caucasian volunteers, deemed healthy based on a clinical history, physical
             examination, ECG, vital signs, and laboratory tests of blood and urine.

          2. 18 to 45 years of age.

          3. Normal body weight (BMI; Quetelet index) in the range 18 to 30.1 kg/m2 at screening.

          4. Blood pressure and heart rate in the supine position prior to randomisation must be
             within the ranges 90-140 mm Hg systolic, 60-90 mm Hg diastolic; heart rate 45-100
             beats/min.

          5. Sufficient intelligence to understand the nature of the trial and any hazards of
             participating in it. Ability to communicate satisfactorily with the Investigator and
             to participate in, and comply with the requirements of, the entire trial.

          6. Willingness to give written consent to participate, after reading the information and
             consent form, and after having the opportunity to discuss the trial with the
             Investigator or his delegate.

          7. Willingness to give written consent to have data entered into the Overvolunteering
             Prevention System.

          8. Willingness to agree to the contraceptive requirements of the study from the first
             dose until 120 days after the last dose of study medication.

        Exclusion Criteria:

          1. Administration of a licensed or unlicensed medicinal product as part of another
             clinical trial within the 3 months before, or within 5 half-lives of, their first dose
             of study medication, whichever is longer, or is currently in the follow-up period for
             any clinical trial.

          2. Clinically relevant abnormal medical history, concurrent medical condition, acute or
             chronic illness or history of chronic illness (such as diabetes mellitus or other
             abnormalities of glucose homeostasis) sufficient to invalidate the subject's
             participation in the trial or make it unnecessarily hazardous.

          3. Past surgery (e.g., stomach bypass) or medical condition that might affect absorption
             of study drug taken orally.

          4. Presence of abnormal physical findings, ECG, or laboratory values at the pre-trial
             screening assessment that could interfere with the objectives of the trial or the
             safety of the subject.

          5. Loss of more than 400 mL of blood within 3 months before admission.

          6. Clinically relevant history of vital organ disease or other disease of an organ or the
             central nervous system.

          7. Current or previous medical or psychiatric disorder, condition or history of such
             (e.g., seizures) that, in the opinion of the Investigator or the Sponsor, would
             increase the risk associated with study participation, or impair the subject's ability
             to participate or complete this study.

          8. Positive test for hepatitis B, hepatitis C or HIV.

          9. Febrile illness within 1 week before the first dose of study medication.

         10. History of severe allergy, non-allergic drug reactions, severe adverse reaction to any
             drug, or multiple drug allergies.

         11. Subjects with hypersensitivity to any ingredient of the study medication, including
             the active ingredient, emodepside.

         12. Presence or history of drug or alcohol abuse in the last 10 years, or intake of more
             than 21 units of alcohol weekly.

         13. Regular daily consumption of more than one liter of xanthine-containing beverages.

         14. Regular daily consumption of more than 5 cigarettes daily, or use more than 3 grams
             (1/8 ounce) of tobacco.

         15. Use of a prescription medicine during the 28 days before the first dose of study
             medication or use of an over-the-counter medicine (with exception of acetaminophen
             [paracetamol]), during the 7 days before the first dose of study medication.

         16. Use of dietary supplements or herbal remedies (such as St John's Wort) that are known
             to be inducers or inhibitors of CYP3A4, or other co-medications known to be relevant
             substrates of CYP3A4, during the 28 days before the first dose of study medication
             (see list in the Study Procedures Manual).

         17. Use of dietary supplements or herbal remedies (such as St John's Wort) that are known
             to be strong inhibitors of P-gp, or other co-medications known to be relevant
             substrates of P-gp, during the 28 days before the first dose of study medication (see
             list in the Study Procedures Manual).

         18. Relevant pathological abnormalities in the ECG at screening, such as a second or
             third-degree atrioventricular (AV) block or prolongation of the QRS complex over 120
             msec or QTc-interval over 450 msec (corrected using Bazett's [QTcB] or Fridericia's
             [QTcF] formulae).

         19. Evidence of drug abuse (via urine testing) at the screening assessment or admission to
             the ward.

         20. Use of excluded therapies that may impact on the interpretation of study results in
             the opinion of the Investigator or Sponsor.

         21. Objection by General Practitioner (GP) to subject entering trial.

         22. History of residing for 6 or more continuous months, within the last 3 years, in
             regions with endemic parasitic infections as determined by the Investigator.

         23. Possibility that subject will not cooperate with the requirements of the protocol.

         24. No contact lenses wear within 1 month before dosing. Wearing contact lenses is not
             permitted during the study.

         25. Any ocular disorder for which topical ocular therapy is currently or chronically
             prescribed, including inflammatory eye disease (dry eye allergic conjunctivitis
             [seasonal allergic conjunctivitis, vernal keratoconjunctivitis, atopic
             keratoconjunctivitis], uveitis and glaucoma).

         26. Past history of ocular disease requiring ongoing treatment.

         27. Past ocular surgery including laser or other refractive corneal surgery.

         28. Evidence of eye irritation, visual difficulties, corneal opacity, ocular surface
             (corneal or conjunctival damage, with or without ocular symptoms).

         29. Evidence of narrow anterior chamber angles causing increased risk of acute glaucoma.

         30. Evidence of ocular media opacity including lens opacity/vitreous opacities.

         31. Evidence of retinal or optic nerve pathology.

         32. Evidence of pronounced colour blindness, as indicated by an Ishihara score of 9/13 or
             below.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only male subjects will be included</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Dennison, PhD MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Limited</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <results_first_submitted>February 19, 2020</results_first_submitted>
  <results_first_submitted_qc>April 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 15, 2020</results_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emodepside</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03383614/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03383614/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>24 healthy subjects were randomized and received study drug or matching placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: 5mg EMODEPSIDE OD</title>
          <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: 10mg EMODEPSIDE OD</title>
          <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: 10mg EMODEPSIDE BID</title>
          <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="P4">
          <title>Placebo Group</title>
          <description>6 subjects with matching placebo (2 subjects per dose group)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: 5mg EMODEPSIDE OD</title>
          <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: 10mg EMODEPSIDE OD</title>
          <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: 10mg EMODEPSIDE BID</title>
          <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="B4">
          <title>Placebo Group</title>
          <description>6 subjects with matching placebo (2 subjects per dose group)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.0" lower_limit="19" upper_limit="41"/>
                    <measurement group_id="B2" value="33.3" lower_limit="19" upper_limit="42"/>
                    <measurement group_id="B3" value="28.0" lower_limit="20" upper_limit="43"/>
                    <measurement group_id="B4" value="32.7" lower_limit="27" upper_limit="41"/>
                    <measurement group_id="B5" value="31.3" lower_limit="19" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179.3" spread="4.18"/>
                    <measurement group_id="B2" value="179.7" spread="4.59"/>
                    <measurement group_id="B3" value="181.8" spread="6.74"/>
                    <measurement group_id="B4" value="182.7" spread="8.80"/>
                    <measurement group_id="B5" value="180.9" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.18" spread="6.204"/>
                    <measurement group_id="B2" value="77.70" spread="17.570"/>
                    <measurement group_id="B3" value="75.23" spread="9.520"/>
                    <measurement group_id="B4" value="74.73" spread="8.999"/>
                    <measurement group_id="B5" value="74.96" spread="10.807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.48" spread="2.520"/>
                    <measurement group_id="B2" value="23.88" spread="4.392"/>
                    <measurement group_id="B3" value="22.72" spread="2.111"/>
                    <measurement group_id="B4" value="22.33" spread="0.882"/>
                    <measurement group_id="B5" value="22.85" spread="2.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smokers</title>
          <description>Includes only those subjects who smoked.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weekly alcohol consumption (units)</title>
          <population>Includes only those subjects who drank alcohol-containing beverages.</population>
          <units>units/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="4"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="3.79"/>
                    <measurement group_id="B2" value="3.3" spread="2.31"/>
                    <measurement group_id="B3" value="7.0" spread="3.46"/>
                    <measurement group_id="B4" value="5.8" spread="2.17"/>
                    <measurement group_id="B5" value="6.1" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Xanthine</title>
          <population>Includes only those subjects who drank xanthine-containing beverages.</population>
          <units>mL/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="441.7" spread="245.80"/>
                    <measurement group_id="B2" value="562.5" spread="239.36"/>
                    <measurement group_id="B3" value="283.3" spread="104.08"/>
                    <measurement group_id="B4" value="300.0" spread="122.47"/>
                    <measurement group_id="B5" value="397.4" spread="209.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events</title>
        <description>Death, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs).</description>
        <time_frame>up to 120 days</time_frame>
        <population>Adverse events were determined in the Safety population. Adverse events were monitored from Screening (Day -28 and until Day -3) to Follow-up (up to Day 120 ±2 days).
AE=adverse event; OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events</title>
          <description>Death, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs).</description>
          <population>Adverse events were determined in the Safety population. Adverse events were monitored from Screening (Day -28 and until Day -3) to Follow-up (up to Day 120 ±2 days).
AE=adverse event; OD=once daily; BID=twice daily.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawals from the study owing to a TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Adverse Event Severity</title>
        <description>Number of subjects with a TEAE, by highest level of severity.</description>
        <time_frame>Up to 120 days</time_frame>
        <population>Adverse events were determined in the Safety population. Adverse events were monitored from Screening (Day -28 and until Day -3) to Follow-up (up to Day 120 ±2 days).
AE=adverse event; OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Adverse Event Severity</title>
          <description>Number of subjects with a TEAE, by highest level of severity.</description>
          <population>Adverse events were determined in the Safety population. Adverse events were monitored from Screening (Day -28 and until Day -3) to Follow-up (up to Day 120 ±2 days).
AE=adverse event; OD=once daily; BID=twice daily.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Vital Signs Findings</title>
        <description>Vital signs included heart rate, systolic and diastolic blood pressure and temperature.</description>
        <time_frame>up to 120 days</time_frame>
        <population>Vital signs were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit.
OD=once daily; BID=twice daily; HR=heart rate; BP=blood pressure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Vital Signs Findings</title>
          <description>Vital signs included heart rate, systolic and diastolic blood pressure and temperature.</description>
          <population>Vital signs were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit.
OD=once daily; BID=twice daily; HR=heart rate; BP=blood pressure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant change in HR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant change in systolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant change in diastolic BP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant change in temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With 12-lead Electrocardiogram Findings</title>
        <description>The following variables were recorded in 12-lead ECGs: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.</description>
        <time_frame>up to 30 days</time_frame>
        <population>Twelve-lead ECG assessments were made predose on Day −1 and at regular timepoints until Follow-up (Day 30).
ECG=electrocardiogram; OD=once daily; BID=twice daily; PR=PR interval.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With 12-lead Electrocardiogram Findings</title>
          <description>The following variables were recorded in 12-lead ECGs: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.</description>
          <population>Twelve-lead ECG assessments were made predose on Day −1 and at regular timepoints until Follow-up (Day 30).
ECG=electrocardiogram; OD=once daily; BID=twice daily; PR=PR interval.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant changes in ventricular rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant changes in PR interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant changes in QRS interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant changes in QTcB interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Clinical Laboratory Tests Findings</title>
        <description>Clinical laboratory parameters included clinical chemistry, hematology, coagulation and urinalysis.</description>
        <time_frame>up to 120 days</time_frame>
        <population>Clinical laboratory parameters were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit.
OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Clinical Laboratory Tests Findings</title>
          <description>Clinical laboratory parameters included clinical chemistry, hematology, coagulation and urinalysis.</description>
          <population>Clinical laboratory parameters were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit.
OD=once daily; BID=twice daily.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant clinical chemistry changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant hematology changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant coagulation changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant urinalysis changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Ophthalmology Assessment Findings</title>
        <description>Ophthalmological examinations at Screening Visit 2 and Day 10 were done at a specialist eye hospital by a Consultant Ophthalmologist, or their assistant. Examinations included: ocular symptoms and history, autorefraction, best correct visual acuity, colour vision, Amsler grid, ocular alignment and motility, confrontation visual field, slit-lamp, measurement of intraocular pressure and an optical coherence tomography test.</description>
        <time_frame>up to 10 days</time_frame>
        <population>Ophthalmological assessments were performed at the second screening visit after all other eligibility criteria had been met and on Day 10.
OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Ophthalmology Assessment Findings</title>
          <description>Ophthalmological examinations at Screening Visit 2 and Day 10 were done at a specialist eye hospital by a Consultant Ophthalmologist, or their assistant. Examinations included: ocular symptoms and history, autorefraction, best correct visual acuity, colour vision, Amsler grid, ocular alignment and motility, confrontation visual field, slit-lamp, measurement of intraocular pressure and an optical coherence tomography test.</description>
          <population>Ophthalmological assessments were performed at the second screening visit after all other eligibility criteria had been met and on Day 10.
OD=once daily; BID=twice daily.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinically significant ocular symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant Amsler grid assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Physical Examination Findings</title>
        <description>Abnormal or clinically significant physical examination findings during the study or reported as an adverse event.</description>
        <time_frame>up to 120 days</time_frame>
        <population>Physical and neurological examinations were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit. Results are reported for subjects experiencing abnormal result/AE, as opposed to individual events.
OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Physical Examination Findings</title>
          <description>Abnormal or clinically significant physical examination findings during the study or reported as an adverse event.</description>
          <population>Physical and neurological examinations were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit. Results are reported for subjects experiencing abnormal result/AE, as opposed to individual events.
OD=once daily; BID=twice daily.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal physical examination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical examination reported as an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Neurological Examination Findings</title>
        <description>Abnormal or clinically significant neurological examination findings during the study or reported as an adverse event.</description>
        <time_frame>up to 120 days</time_frame>
        <population>Neurological examinations were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit.
OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Neurological Examination Findings</title>
          <description>Abnormal or clinically significant neurological examination findings during the study or reported as an adverse event.</description>
          <population>Neurological examinations were measured pre-dose on Day -1, at regular time points until Follow-up (Day 30), and at each long-term follow-up visit.
OD=once daily; BID=twice daily.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal neurological examination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological examination reported as an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Emodepside Plasma Pharmacokinetic Concentration−Time Data During the Repeated Dosing Period</title>
        <description>Summary of geometric mean emodepside plasma pharmacokinetic concentration−time data (ng/mL) during the repeated dosing period (Days 0-9) in healthy men.
Subjects in the 10 mg emodepside BID dosing group had twice-daily doses on Days 0-8 and a single dose on the morning of Day 9. Therefore, the Day 9, 24 h post-dose value was not comparable to the previous value in that dosing group.</description>
        <time_frame>From Day 1, pre-dose to Day 9, 24 hours post-dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Emodepside Plasma Pharmacokinetic Concentration−Time Data During the Repeated Dosing Period</title>
          <description>Summary of geometric mean emodepside plasma pharmacokinetic concentration−time data (ng/mL) during the repeated dosing period (Days 0-9) in healthy men.
Subjects in the 10 mg emodepside BID dosing group had twice-daily doses on Days 0-8 and a single dose on the morning of Day 9. Therefore, the Day 9, 24 h post-dose value was not comparable to the previous value in that dosing group.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.77" spread="35.8"/>
                    <measurement group_id="O2" value="15.78" spread="42.9"/>
                    <measurement group_id="O3" value="45.94" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.24" spread="31.1"/>
                    <measurement group_id="O2" value="28.80" spread="40.0"/>
                    <measurement group_id="O3" value="64.62" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.22" spread="35.0"/>
                    <measurement group_id="O2" value="39.08" spread="45.6"/>
                    <measurement group_id="O3" value="84.65" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.81" spread="37.4"/>
                    <measurement group_id="O2" value="47.38" spread="42.2"/>
                    <measurement group_id="O3" value="98.01" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.46" spread="36.3"/>
                    <measurement group_id="O2" value="60.07" spread="42.9"/>
                    <measurement group_id="O3" value="120.98" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.68" spread="36.7"/>
                    <measurement group_id="O2" value="70.88" spread="39.6"/>
                    <measurement group_id="O3" value="137.60" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.57" spread="31.4"/>
                    <measurement group_id="O2" value="83.31" spread="43.0"/>
                    <measurement group_id="O3" value="149.41" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.91" spread="36.8"/>
                    <measurement group_id="O2" value="91.63" spread="42.4"/>
                    <measurement group_id="O3" value="179.90" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.73" spread="35.1"/>
                    <measurement group_id="O2" value="97.11" spread="44.0"/>
                    <measurement group_id="O3" value="184.94" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, 24 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.76" spread="36.6"/>
                    <measurement group_id="O2" value="108.17" spread="49.1"/>
                    <measurement group_id="O3" value="176.10" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUClast of Emodepside in Plasma</title>
        <description>Summary of AUClast of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration.
PK=pharmacokinetic. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUClast in plasma after the last dose (Day 9)</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUClast of Emodepside in Plasma</title>
          <description>Summary of AUClast of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration.
PK=pharmacokinetic. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19359" spread="29.9"/>
                    <measurement group_id="O2" value="40655" spread="43.5"/>
                    <measurement group_id="O3" value="59554" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUClast/D of Emodepside in Plasma</title>
        <description>Summary of AUClast/D of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast/D: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUClast /D in plasma after the last dose (Day 9)</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUClast/D of Emodepside in Plasma</title>
          <description>Summary of AUClast/D of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast/D: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>h*ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3872" spread="29.9"/>
                    <measurement group_id="O2" value="4065" spread="43.5"/>
                    <measurement group_id="O3" value="5955" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUClast,Norm of Emodepside in Plasma</title>
        <description>Summary of AUClast,norm of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast,norm: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUClast,norm in plasma after the last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUClast,Norm of Emodepside in Plasma</title>
          <description>Summary of AUClast,norm of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast,norm: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>(h*ng/mL)/(mg*kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" spread="33.1"/>
                    <measurement group_id="O2" value="52.9" spread="69.5"/>
                    <measurement group_id="O3" value="79.1" spread="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC12 of Emodepside in Plasma</title>
        <description>Summary of AUC12 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12: the area under the concentration-time curve from time zero (pre-dose) to 12h.
Note: AUC12 was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUC12 in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC12 of Emodepside in Plasma</title>
          <description>Summary of AUC12 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12: the area under the concentration-time curve from time zero (pre-dose) to 12h.
Note: AUC12 was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>BID=twice daily.</population>
          <units>h*ng/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="742" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2810" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC12/D of Emodepside in Plasma</title>
        <description>Summary of AUC12/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12/D: the area under the concentration-time curve from time zero (pre-dose) to 12h, corrected for dose.
Note: AUC12/D was collected only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUC12/D in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC12/D of Emodepside in Plasma</title>
          <description>Summary of AUC12/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12/D: the area under the concentration-time curve from time zero (pre-dose) to 12h, corrected for dose.
Note: AUC12/D was collected only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>BID=twice daily.</population>
          <units>h*ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC12,Norm of Emodepside in Plasma</title>
        <description>Summary of AUC12,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC12,norm: the area under the concentration−time curve from time zero (pre-dose) to 12 h corrected by dose and body weight.
Note: AUC12,norm was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUC12,norm in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC12,Norm of Emodepside in Plasma</title>
          <description>Summary of AUC12,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC12,norm: the area under the concentration−time curve from time zero (pre-dose) to 12 h corrected by dose and body weight.
Note: AUC12,norm was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>BID=twice daily.</population>
          <units>(h*ng/mL)/(mg*kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.985" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC24 of Emodepside in Plasma</title>
        <description>Summary of AUC24 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24: the area under the concentration-time curve from time zero (pre-dose) to 24 h.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUC24 in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC24 of Emodepside in Plasma</title>
          <description>Summary of AUC24 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24: the area under the concentration-time curve from time zero (pre-dose) to 24 h.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="574" spread="19.7"/>
                    <measurement group_id="O2" value="1135" spread="32.7"/>
                    <measurement group_id="O3" value="1428" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1689" spread="31.3"/>
                    <measurement group_id="O2" value="3487" spread="44.2"/>
                    <measurement group_id="O3" value="4897" spread="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC24/D of Emodepside in Plasma</title>
        <description>Summary of AUC24/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24/D: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUC24/D in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC24/D of Emodepside in Plasma</title>
          <description>Summary of AUC24/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24/D: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>h*ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="19.7"/>
                    <measurement group_id="O2" value="113" spread="32.7"/>
                    <measurement group_id="O3" value="71.4" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338" spread="31.3"/>
                    <measurement group_id="O2" value="349" spread="44.2"/>
                    <measurement group_id="O3" value="490" spread="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC24,Norm of Emodepside in Plasma</title>
        <description>Summary of AUC24,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC24,norm: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>AUC24,norm in plasma at Day 0 and Day 9</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC24,Norm of Emodepside in Plasma</title>
          <description>Summary of AUC24,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC24,norm: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>(h*ng/mL)/(mg*kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="21.5"/>
                    <measurement group_id="O2" value="1.48" spread="56.7"/>
                    <measurement group_id="O3" value="0.948" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" spread="34.1"/>
                    <measurement group_id="O2" value="4.54" spread="69.7"/>
                    <measurement group_id="O3" value="6.50" spread="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cmax of Emodepside in Plasma</title>
        <description>Summary of Cmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>Cmax in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cmax of Emodepside in Plasma</title>
          <description>Summary of Cmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" spread="17.8"/>
                    <measurement group_id="O2" value="186" spread="21.3"/>
                    <measurement group_id="O3" value="160" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="17.9"/>
                    <measurement group_id="O2" value="287" spread="39.7"/>
                    <measurement group_id="O3" value="349" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cmax/D of Emodepside in Plasma</title>
        <description>Summary of Cmax/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax/D: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>Cmax/D in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cmax/D of Emodepside in Plasma</title>
          <description>Summary of Cmax/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax/D: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="17.8"/>
                    <measurement group_id="O2" value="18.6" spread="21.3"/>
                    <measurement group_id="O3" value="16.0" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="17.9"/>
                    <measurement group_id="O2" value="28.7" spread="39.7"/>
                    <measurement group_id="O3" value="34.9" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cmax,Norm of Emodepside in Plasma</title>
        <description>Summary of Cmax,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax,norm: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>Cmax,norm in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cmax,Norm of Emodepside in Plasma</title>
          <description>Summary of Cmax,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax,norm: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>(ng/mL)*(mg*kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.261" spread="18.4"/>
                    <measurement group_id="O2" value="0.242" spread="42.8"/>
                    <measurement group_id="O3" value="0.212" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.416" spread="20.6"/>
                    <measurement group_id="O2" value="0.374" spread="65.4"/>
                    <measurement group_id="O3" value="0.464" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Ctrough of Emodepside in Plasma</title>
        <description>Summary of Ctrough (log-transformed) of emodepside after last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Ctrough: trough plasma concentration (measured concentration at the end of a dosing interval on Day 9 [taken directly before next administration]) obtained directly from the concentration-time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>Ctrough in plasma after the last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Ctrough of Emodepside in Plasma</title>
          <description>Summary of Ctrough (log-transformed) of emodepside after last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Ctrough: trough plasma concentration (measured concentration at the end of a dosing interval on Day 9 [taken directly before next administration]) obtained directly from the concentration-time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="36.8"/>
                    <measurement group_id="O2" value="97.1" spread="50.8"/>
                    <measurement group_id="O3" value="185" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Tmax of Emodepside in Plasma</title>
        <description>Summary of tmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
tmax: the time at which Cmax was apparent, identified by inspection of the drug concentration vs. time data.</description>
        <time_frame>tmax in plasma after the first (Day 0) and last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Tmax of Emodepside in Plasma</title>
          <description>Summary of tmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
tmax: the time at which Cmax was apparent, identified by inspection of the drug concentration vs. time data.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.25" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.25" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.50" lower_limit="1.03" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The t1/2 of Emodepside in Plasma</title>
        <description>Summary of t1/2 of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2: terminal half-life. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>t1/2 in plasma after the last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The t1/2 of Emodepside in Plasma</title>
          <description>Summary of t1/2 of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2: terminal half-life. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419" spread="42.6"/>
                    <measurement group_id="O2" value="450" spread="30.6"/>
                    <measurement group_id="O3" value="508" spread="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The t1/2,(0-24) of Emodepside in Plasma</title>
        <description>Summary of t1/2,(0-24) of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2,(0-24): half-life calculated from the terminal slope of the log concentration-time (0-24h) curve.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>t1/2,(0-24) in plasma after the last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The t1/2,(0-24) of Emodepside in Plasma</title>
          <description>Summary of t1/2,(0-24) of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2,(0-24): half-life calculated from the terminal slope of the log concentration-time (0-24h) curve.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="52.4"/>
                    <measurement group_id="O2" value="18.4" spread="30.0"/>
                    <measurement group_id="O3" value="33.2" spread="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The λz of Emodepside in Plasma</title>
        <description>Summary of λz of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
λz: terminal rate constant. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>λz in plasma after the last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The λz of Emodepside in Plasma</title>
          <description>Summary of λz of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
λz: terminal rate constant. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00166" spread="42.6"/>
                    <measurement group_id="O2" value="0.00154" spread="30.6"/>
                    <measurement group_id="O3" value="0.00137" spread="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The CLss/F of Emodepside in Plasma</title>
        <description>Summary of CLss/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
CLss/F: apparent total clearance from plasma on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>CLss/F in plasma after the last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The CLss/F of Emodepside in Plasma</title>
          <description>Summary of CLss/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
CLss/F: apparent total clearance from plasma on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="31.3"/>
                    <measurement group_id="O2" value="2.87" spread="44.2"/>
                    <measurement group_id="O3" value="3.56" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Vz/F of Emodepside in Plasma</title>
        <description>Summary of Vz/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Vz/F: apparent volume of distribution on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>Vz/F in plasma after the last (Day 9) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Vz/F of Emodepside in Plasma</title>
          <description>Summary of Vz/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Vz/F: apparent volume of distribution on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>litre(s)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1788" spread="74.2"/>
                    <measurement group_id="O2" value="1861" spread="68.5"/>
                    <measurement group_id="O3" value="2607" spread="102.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The MRTlast of Emodepside in Plasma</title>
        <description>Summary of MRTlast of emodepside after the first (Day 0) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose.
MRTlast: mean residence time from time zero (pre-dose) to the time of last quantifiable concentration (measurable up to 24h after dosing on Day 0).
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
        <time_frame>MRTlast in plasma after the first (Day 0) dose</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The MRTlast of Emodepside in Plasma</title>
          <description>Summary of MRTlast of emodepside after the first (Day 0) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose.
MRTlast: mean residence time from time zero (pre-dose) to the time of last quantifiable concentration (measurable up to 24h after dosing on Day 0).
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.28" spread="10.7"/>
                    <measurement group_id="O2" value="7.00" spread="11.0"/>
                    <measurement group_id="O3" value="10.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rac(AUC12) of Emodepside in Plasma</title>
        <description>Summary of emodepside plasma Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC12): accumulation ratio calculated from AUC12, where AUC12 is the area under the concentration−time curve from time zero (pre-dose) to 12h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).
Note: Rac(AUC12) was calculated only in Cohort 3.</description>
        <time_frame>Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9)</time_frame>
        <population>BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rac(AUC12) of Emodepside in Plasma</title>
          <description>Summary of emodepside plasma Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC12): accumulation ratio calculated from AUC12, where AUC12 is the area under the concentration−time curve from time zero (pre-dose) to 12h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).
Note: Rac(AUC12) was calculated only in Cohort 3.</description>
          <population>BID=twice daily.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rac(AUC24) of Emodepside in Plasma</title>
        <description>Summary of emodepside plasma Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC24): accumulation ratio calculated from AUC24, where AUC24 is the area under the concentration-time curve from time zero (pre-dose) to 24h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).</description>
        <time_frame>Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9)</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rac(AUC24) of Emodepside in Plasma</title>
          <description>Summary of emodepside plasma Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC24): accumulation ratio calculated from AUC24, where AUC24 is the area under the concentration-time curve from time zero (pre-dose) to 24h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="16.1"/>
                    <measurement group_id="O2" value="3.09" spread="11.3"/>
                    <measurement group_id="O3" value="3.47" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rac(Cmax) of Emodepside in Plasma</title>
        <description>Summary of emodepside plasma Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(Cmax): accumulation ratio calculated from Cmax, where Cmax is the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).</description>
        <time_frame>Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9)</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Emodepside 5 mg OD</title>
            <description>Emodepside (BAY 44-4400) 5 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Emodepside 10 mg OD</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, once daily in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Emodepside 10 mg BID</title>
            <description>Emodepside (BAY 44-4400) 10 mg orally, twice a day (morning and evening) in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rac(Cmax) of Emodepside in Plasma</title>
          <description>Summary of emodepside plasma Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(Cmax): accumulation ratio calculated from Cmax, where Cmax is the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="16.5"/>
                    <measurement group_id="O2" value="1.58" spread="24.1"/>
                    <measurement group_id="O3" value="2.21" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Concentration at Day -1</title>
        <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.</description>
        <time_frame>Mean glucose at Day -1 after repeated once or twice daily dosing</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Concentration at Day -1</title>
          <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.286"/>
                    <measurement group_id="O2" value="4.68" spread="0.349"/>
                    <measurement group_id="O3" value="4.80" spread="0.245"/>
                    <measurement group_id="O4" value="4.77" spread="0.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-23 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="0.308"/>
                    <measurement group_id="O2" value="4.85" spread="0.259"/>
                    <measurement group_id="O3" value="4.85" spread="0.281"/>
                    <measurement group_id="O4" value="4.92" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-22 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="0.378"/>
                    <measurement group_id="O2" value="4.72" spread="0.371"/>
                    <measurement group_id="O3" value="4.72" spread="0.279"/>
                    <measurement group_id="O4" value="4.82" spread="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-20 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="0.388"/>
                    <measurement group_id="O2" value="4.57" spread="0.207"/>
                    <measurement group_id="O3" value="4.55" spread="0.207"/>
                    <measurement group_id="O4" value="4.73" spread="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="0.712"/>
                    <measurement group_id="O2" value="5.55" spread="0.451"/>
                    <measurement group_id="O3" value="5.52" spread="0.556"/>
                    <measurement group_id="O4" value="5.48" spread="0.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Concentration at Day 0</title>
        <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.</description>
        <time_frame>Mean glucose after repeated once or twice daily dosing for up to 10 days</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Concentration at Day 0</title>
          <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="0.321"/>
                    <measurement group_id="O2" value="4.85" spread="0.409"/>
                    <measurement group_id="O3" value="4.85" spread="0.351"/>
                    <measurement group_id="O4" value="4.85" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="0.367"/>
                    <measurement group_id="O2" value="5.57" spread="0.816"/>
                    <measurement group_id="O3" value="5.42" spread="0.445"/>
                    <measurement group_id="O4" value="4.78" spread="0.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="0.327"/>
                    <measurement group_id="O2" value="5.28" spread="0.508"/>
                    <measurement group_id="O3" value="5.27" spread="0.472"/>
                    <measurement group_id="O4" value="4.70" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" spread="0.378"/>
                    <measurement group_id="O2" value="4.75" spread="0.274"/>
                    <measurement group_id="O3" value="4.82" spread="0.279"/>
                    <measurement group_id="O4" value="4.70" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="0.268"/>
                    <measurement group_id="O2" value="6.22" spread="0.343"/>
                    <measurement group_id="O3" value="5.57" spread="0.554"/>
                    <measurement group_id="O4" value="6.27" spread="0.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="0.314"/>
                    <measurement group_id="O2" value="4.88" spread="0.264"/>
                    <measurement group_id="O3" value="4.87" spread="0.273"/>
                    <measurement group_id="O4" value="4.97" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Concentration at Day 9</title>
        <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.</description>
        <time_frame>Mean glucose at Day 9 after repeated once or twice daily dosing</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Concentration at Day 9</title>
          <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" spread="0.306"/>
                    <measurement group_id="O2" value="4.95" spread="0.362"/>
                    <measurement group_id="O3" value="4.97" spread="0.314"/>
                    <measurement group_id="O4" value="4.67" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="0.352"/>
                    <measurement group_id="O2" value="5.98" spread="1.972"/>
                    <measurement group_id="O3" value="5.65" spread="0.771"/>
                    <measurement group_id="O4" value="4.80" spread="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="0.250"/>
                    <measurement group_id="O2" value="5.72" spread="1.543"/>
                    <measurement group_id="O3" value="5.57" spread="0.761"/>
                    <measurement group_id="O4" value="4.74" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="0.363"/>
                    <measurement group_id="O2" value="4.62" spread="0.377"/>
                    <measurement group_id="O3" value="5.08" spread="0.662"/>
                    <measurement group_id="O4" value="4.70" spread="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="0.319"/>
                    <measurement group_id="O2" value="6.00" spread="0.745"/>
                    <measurement group_id="O3" value="7.03" spread="1.111"/>
                    <measurement group_id="O4" value="6.02" spread="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="0.264"/>
                    <measurement group_id="O2" value="5.10" spread="0.490"/>
                    <measurement group_id="O3" value="5.17" spread="0.273"/>
                    <measurement group_id="O4" value="4.82" spread="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="0.194"/>
                    <measurement group_id="O2" value="5.07" spread="0.532"/>
                    <measurement group_id="O3" value="5.10" spread="0.390"/>
                    <measurement group_id="O4" value="4.90" spread="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="0.350"/>
                    <measurement group_id="O2" value="5.13" spread="0.589"/>
                    <measurement group_id="O3" value="5.03" spread="0.308"/>
                    <measurement group_id="O4" value="5.03" spread="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="0.276"/>
                    <measurement group_id="O2" value="5.10" spread="0.540"/>
                    <measurement group_id="O3" value="4.85" spread="0.315"/>
                    <measurement group_id="O4" value="4.87" spread="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="0.352"/>
                    <measurement group_id="O2" value="4.98" spread="0.458"/>
                    <measurement group_id="O3" value="5.05" spread="0.288"/>
                    <measurement group_id="O4" value="4.90" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Concentration at Day 30</title>
        <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.</description>
        <time_frame>Mean glucose at Day 30 after repeated once or twice daily dosing</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose Concentration at Day 30</title>
          <description>Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="0.288"/>
                    <measurement group_id="O2" value="5.23" spread="0.993"/>
                    <measurement group_id="O3" value="4.97" spread="0.234"/>
                    <measurement group_id="O4" value="4.53" spread="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insulin Concentration at Day -1</title>
        <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.</description>
        <time_frame>Mean insulin concentration at Day-1 after repeated once or twice daily dosing</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insulin Concentration at Day -1</title>
          <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="8.60"/>
                    <measurement group_id="O2" value="25.8" spread="8.11"/>
                    <measurement group_id="O3" value="33.2" spread="17.90"/>
                    <measurement group_id="O4" value="32.3" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-23 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="3.87"/>
                    <measurement group_id="O2" value="26.2" spread="7.73"/>
                    <measurement group_id="O3" value="28.0" spread="11.33"/>
                    <measurement group_id="O4" value="26.5" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-22 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="6.69"/>
                    <measurement group_id="O2" value="25.7" spread="8.91"/>
                    <measurement group_id="O3" value="28.3" spread="14.50"/>
                    <measurement group_id="O4" value="33.0" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-20 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="6.02"/>
                    <measurement group_id="O2" value="22.7" spread="7.97"/>
                    <measurement group_id="O3" value="24.3" spread="9.18"/>
                    <measurement group_id="O4" value="24.5" spread="12.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.5" spread="54.14"/>
                    <measurement group_id="O2" value="157.0" spread="81.51"/>
                    <measurement group_id="O3" value="204.7" spread="78.37"/>
                    <measurement group_id="O4" value="136.5" spread="64.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insulin Concentration at Day 0</title>
        <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.</description>
        <time_frame>Mean insulin concentration at Day 0 after repeated once or twice daily dosing</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insulin Concentration at Day 0</title>
          <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="15.41"/>
                    <measurement group_id="O2" value="29.3" spread="5.09"/>
                    <measurement group_id="O3" value="32.2" spread="14.34"/>
                    <measurement group_id="O4" value="30.5" spread="12.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="3.79"/>
                    <measurement group_id="O2" value="23.2" spread="10.85"/>
                    <measurement group_id="O3" value="29.2" spread="14.86"/>
                    <measurement group_id="O4" value="33.0" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="5.20"/>
                    <measurement group_id="O2" value="25.3" spread="9.99"/>
                    <measurement group_id="O3" value="36.3" spread="20.39"/>
                    <measurement group_id="O4" value="31.2" spread="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="5.01"/>
                    <measurement group_id="O2" value="21.7" spread="5.39"/>
                    <measurement group_id="O3" value="27.7" spread="11.69"/>
                    <measurement group_id="O4" value="20.2" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.2" spread="67.59"/>
                    <measurement group_id="O2" value="203.2" spread="83.22"/>
                    <measurement group_id="O3" value="175.3" spread="64.59"/>
                    <measurement group_id="O4" value="195.0" spread="88.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="15.49"/>
                    <measurement group_id="O2" value="41.2" spread="14.51"/>
                    <measurement group_id="O3" value="30.3" spread="11.43"/>
                    <measurement group_id="O4" value="35.2" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insulin Concentration at Day 9</title>
        <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.</description>
        <time_frame>Mean insulin concentration at Day 9 after repeated once or twice daily dosing</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insulin Concentration at Day 9</title>
          <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="8.62"/>
                    <measurement group_id="O2" value="32.7" spread="15.02"/>
                    <measurement group_id="O3" value="29.2" spread="10.19"/>
                    <measurement group_id="O4" value="31.3" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="9.66"/>
                    <measurement group_id="O2" value="24.4" spread="15.39"/>
                    <measurement group_id="O3" value="22.2" spread="8.89"/>
                    <measurement group_id="O4" value="27.8" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="4.84"/>
                    <measurement group_id="O2" value="31.2" spread="10.53"/>
                    <measurement group_id="O3" value="30.2" spread="13.91"/>
                    <measurement group_id="O4" value="29.8" spread="10.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="7.35"/>
                    <measurement group_id="O2" value="28.4" spread="13.24"/>
                    <measurement group_id="O3" value="19.5" spread="9.12"/>
                    <measurement group_id="O4" value="21.8" spread="6.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.2" spread="77.58"/>
                    <measurement group_id="O2" value="143.0" spread="113.7"/>
                    <measurement group_id="O3" value="215.8" spread="128.1"/>
                    <measurement group_id="O4" value="215.7" spread="151.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="11.88"/>
                    <measurement group_id="O2" value="36.5" spread="12.24"/>
                    <measurement group_id="O3" value="32.7" spread="17.44"/>
                    <measurement group_id="O4" value="36.3" spread="13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="5.60"/>
                    <measurement group_id="O2" value="44.8" spread="17.89"/>
                    <measurement group_id="O3" value="36.3" spread="13.59"/>
                    <measurement group_id="O4" value="38.2" spread="19.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="23.53"/>
                    <measurement group_id="O2" value="40.7" spread="13.88"/>
                    <measurement group_id="O3" value="39.8" spread="15.61"/>
                    <measurement group_id="O4" value="38.7" spread="14.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="10.42"/>
                    <measurement group_id="O2" value="39.3" spread="12.31"/>
                    <measurement group_id="O3" value="37.2" spread="17.66"/>
                    <measurement group_id="O4" value="30.0" spread="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="8.63"/>
                    <measurement group_id="O2" value="42.3" spread="17.92"/>
                    <measurement group_id="O3" value="36.0" spread="15.24"/>
                    <measurement group_id="O4" value="33.2" spread="21.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insulin Concentration at Day 30</title>
        <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.</description>
        <time_frame>Mean insulin concentration at Day 30 after repeated once or twice daily dosing</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insulin Concentration at Day 30</title>
          <description>Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="12.50"/>
                    <measurement group_id="O2" value="60.3" spread="90.19"/>
                    <measurement group_id="O3" value="24.3" spread="9.79"/>
                    <measurement group_id="O4" value="29.2" spread="20.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Glucose Concentration at Day -2</title>
        <description>Oral glucose tolerance test: mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
        <time_frame>Mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Glucose Concentration at Day -2</title>
          <description>Oral glucose tolerance test: mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 h (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="0.319"/>
                    <measurement group_id="O2" value="4.92" spread="0.256"/>
                    <measurement group_id="O3" value="4.97" spread="0.294"/>
                    <measurement group_id="O4" value="4.78" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="1.659"/>
                    <measurement group_id="O2" value="7.03" spread="0.301"/>
                    <measurement group_id="O3" value="7.00" spread="0.867"/>
                    <measurement group_id="O4" value="6.48" spread="1.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="1.512"/>
                    <measurement group_id="O2" value="5.05" spread="0.589"/>
                    <measurement group_id="O3" value="5.48" spread="0.608"/>
                    <measurement group_id="O4" value="4.95" spread="0.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" spread="0.979"/>
                    <measurement group_id="O2" value="3.95" spread="0.622"/>
                    <measurement group_id="O3" value="4.22" spread="0.371"/>
                    <measurement group_id="O4" value="4.53" spread="0.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Glucose Concentration at Day 1</title>
        <description>Oral glucose tolerance test: mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
        <time_frame>Mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Glucose Concentration at Day 1</title>
          <description>Oral glucose tolerance test: mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="0.314"/>
                    <measurement group_id="O2" value="4.88" spread="0.264"/>
                    <measurement group_id="O3" value="4.87" spread="0.273"/>
                    <measurement group_id="O4" value="4.97" spread="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.10" spread="1.170"/>
                    <measurement group_id="O2" value="12.37" spread="2.826"/>
                    <measurement group_id="O3" value="12.03" spread="0.989"/>
                    <measurement group_id="O4" value="7.58" spread="2.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="1.600"/>
                    <measurement group_id="O2" value="7.95" spread="1.653"/>
                    <measurement group_id="O3" value="9.25" spread="2.740"/>
                    <measurement group_id="O4" value="5.88" spread="1.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="0.339"/>
                    <measurement group_id="O2" value="3.65" spread="0.362"/>
                    <measurement group_id="O3" value="4.02" spread="0.204"/>
                    <measurement group_id="O4" value="4.15" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Glucose Concentration at Day 8</title>
        <description>Oral glucose tolerance test: mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
        <time_frame>Mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Glucose Concentration at Day 8</title>
          <description>Oral glucose tolerance test: mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="0.314"/>
                    <measurement group_id="O2" value="5.10" spread="0.533"/>
                    <measurement group_id="O3" value="4.90" spread="0.303"/>
                    <measurement group_id="O4" value="4.83" spread="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.02" spread="1.857"/>
                    <measurement group_id="O2" value="11.75" spread="4.574"/>
                    <measurement group_id="O3" value="11.27" spread="2.738"/>
                    <measurement group_id="O4" value="7.77" spread="1.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" spread="1.533"/>
                    <measurement group_id="O2" value="8.98" spread="4.311"/>
                    <measurement group_id="O3" value="8.97" spread="2.837"/>
                    <measurement group_id="O4" value="5.52" spread="0.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="0.965"/>
                    <measurement group_id="O2" value="4.12" spread="0.933"/>
                    <measurement group_id="O3" value="4.52" spread="0.806"/>
                    <measurement group_id="O4" value="4.13" spread="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Glucose Concentration at Day 120</title>
        <description>Oral glucose tolerance test: mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)</description>
        <time_frame>Mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Glucose Concentration at Day 120</title>
          <description>Oral glucose tolerance test: mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 h (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.12" spread="2.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="0.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Insulin Concentration at Day -2</title>
        <description>Oral glucose tolerance test: mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
        <time_frame>Mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Insulin Concentration at Day -2</title>
          <description>Oral glucose tolerance test: mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 h (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="13.81"/>
                    <measurement group_id="O2" value="25.7" spread="8.55"/>
                    <measurement group_id="O3" value="27.0" spread="14.00"/>
                    <measurement group_id="O4" value="29.0" spread="14.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.8" spread="207.66"/>
                    <measurement group_id="O2" value="305.3" spread="65.59"/>
                    <measurement group_id="O3" value="306.7" spread="180.00"/>
                    <measurement group_id="O4" value="338.3" spread="189.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.7" spread="206.08"/>
                    <measurement group_id="O2" value="103.7" spread="32.38"/>
                    <measurement group_id="O3" value="136.0" spread="70.52"/>
                    <measurement group_id="O4" value="186.8" spread="83.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="72.56"/>
                    <measurement group_id="O2" value="17.2" spread="6.11"/>
                    <measurement group_id="O3" value="20.8" spread="7.44"/>
                    <measurement group_id="O4" value="21.8" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Insulin Concentration at Day 1</title>
        <description>Oral glucose tolerance test: mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
        <time_frame>Mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Insulin Concentration at Day 1</title>
          <description>Oral glucose tolerance test: mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="15.49"/>
                    <measurement group_id="O2" value="41.2" spread="14.51"/>
                    <measurement group_id="O3" value="30.3" spread="11.43"/>
                    <measurement group_id="O4" value="35.2" spread="16.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.2" spread="153.67"/>
                    <measurement group_id="O2" value="288.8" spread="171.44"/>
                    <measurement group_id="O3" value="332.2" spread="228.84"/>
                    <measurement group_id="O4" value="606.7" spread="157.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.5" spread="107.14"/>
                    <measurement group_id="O2" value="377.3" spread="224.73"/>
                    <measurement group_id="O3" value="336.2" spread="165.71"/>
                    <measurement group_id="O4" value="238.0" spread="165.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="22.35"/>
                    <measurement group_id="O2" value="30.8" spread="12.35"/>
                    <measurement group_id="O3" value="35.7" spread="4.59"/>
                    <measurement group_id="O4" value="33.8" spread="19.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Insulin Concentration at Day 8</title>
        <description>Oral glucose tolerance test: mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
        <time_frame>Mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Insulin Concentration at Day 8</title>
          <description>Oral glucose tolerance test: mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="9.85"/>
                    <measurement group_id="O2" value="39.3" spread="22.59"/>
                    <measurement group_id="O3" value="34.5" spread="15.83"/>
                    <measurement group_id="O4" value="33.8" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.5" spread="145.61"/>
                    <measurement group_id="O2" value="286.8" spread="179.53"/>
                    <measurement group_id="O3" value="225.3" spread="148.93"/>
                    <measurement group_id="O4" value="690.5" spread="342.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.0" spread="110.23"/>
                    <measurement group_id="O2" value="225.7" spread="101.02"/>
                    <measurement group_id="O3" value="229.8" spread="79.00"/>
                    <measurement group_id="O4" value="238.3" spread="92.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="86.69"/>
                    <measurement group_id="O2" value="63.3" spread="83.32"/>
                    <measurement group_id="O3" value="36.8" spread="21.17"/>
                    <measurement group_id="O4" value="21.7" spread="19.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Insulin Concentration at Day 120</title>
        <description>Oral glucose tolerance test: mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)</description>
        <time_frame>Mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Insulin Concentration at Day 120</title>
          <description>Oral glucose tolerance test: mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 h (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417.8" spread="379.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.8" spread="114.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Drug-related Adverse Events</title>
        <description>Subjects presenting drug-related treatment-emergent adverse events listed by preferred term.
Note: subjects with ≥1 adverse event are counted only once per preferred term.</description>
        <time_frame>Drug-related AEs were reported throughout the study</time_frame>
        <population>OD=once daily; BID=twice daily.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 5mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 10mg EMODEPSIDE OD</title>
            <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: 10mg EMODEPSIDE BID</title>
            <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Placebo Group</title>
            <description>6 subjects with matching placebo (2 subjects per dose group)</description>
          </group>
        </group_list>
        <measure>
          <title>Drug-related Adverse Events</title>
          <description>Subjects presenting drug-related treatment-emergent adverse events listed by preferred term.
Note: subjects with ≥1 adverse event are counted only once per preferred term.</description>
          <population>OD=once daily; BID=twice daily.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visual impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Euphoric mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervousness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored from Screening (Day -28 and until Day -3) to Follow-up (up to Day 120 ±2 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: 5mg EMODEPSIDE OD</title>
          <description>6 subjects with LSF emodepside 5mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: 10mg EMODEPSIDE OD</title>
          <description>6 subjects with LSF emodepside 10mg, OD
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: 10mg EMODEPSIDE BID</title>
          <description>6 subjects with LSF emodepside 10mg, BID
LSF emodepside (BAY 44-4400) oral solution (1mg/mL)</description>
        </group>
        <group group_id="E4">
          <title>Placebo Group</title>
          <description>6 subjects with matching placebo (2 subjects per dose group)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <description>The fistula was downgraded by the investigator to a nonserious AE on 05 NOV 2018; after final database lock. That decision was based on the fact that the subject was hospitalised because of the AE of anal abscess, and not the fistula.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Medical device site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatitis E antibody positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sebaceous cyst excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean Yves Gillon</name_or_title>
      <organization>DNDi</organization>
      <phone>+41.22.906.92.32</phone>
      <email>jygillon@dndi.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

